BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37365294)

  • 1. NPM1 mutation reprograms leukemic transcription network via reshaping TAD topology.
    Lai Q; Hamamoto K; Luo H; Zaroogian Z; Zhou C; Lesperance J; Zha J; Qiu Y; Guryanova OA; Huang S; Xu B
    Leukemia; 2023 Aug; 37(8):1732-1736. PubMed ID: 37365294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia.
    Zhu G; Luo H; Feng Y; Guryanova OA; Xu J; Chen S; Lai Q; Sharma A; Xu B; Zhao Z; Feng R; Ni H; Claxton D; Guo Y; Mesa RA; Qiu Y; Yang FC; Li W; Nimer SD; Huang S; Xu M
    Nat Commun; 2021 Mar; 12(1):1956. PubMed ID: 33782403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice.
    Luo H; Zhu G; Xu J; Lai Q; Yan B; Guo Y; Fung TK; Zeisig BB; Cui Y; Zha J; Cogle C; Wang F; Xu B; Yang FC; Li W; So CWE; Qiu Y; Xu M; Huang S
    Cancer Cell; 2019 Dec; 36(6):645-659.e8. PubMed ID: 31786140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia.
    Luo H; Zhu G; Eshelman MA; Fung TK; Lai Q; Wang F; Zeisig BB; Lesperance J; Ma X; Chen S; Cesari N; Cogle C; Chen B; Xu B; Yang FC; So CWE; Qiu Y; Xu M; Huang S
    Mol Cell; 2022 Feb; 82(4):833-851.e11. PubMed ID: 35180428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
    Kühn MW; Song E; Feng Z; Sinha A; Chen CW; Deshpande AJ; Cusan M; Farnoud N; Mupo A; Grove C; Koche R; Bradner JE; de Stanchina E; Vassiliou GS; Hoshii T; Armstrong SA
    Cancer Discov; 2016 Oct; 6(10):1166-1181. PubMed ID: 27535106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.
    Federici L; Falini B
    Protein Sci; 2013 May; 22(5):545-56. PubMed ID: 23436734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA.
    Gourvest M; De Clara E; Wu HC; Touriol C; Meggetto F; De Thé H; Pyronnet S; Brousset P; Bousquet M
    Leukemia; 2021 Oct; 35(10):2784-2798. PubMed ID: 34131282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia.
    Shi Y; Xue Y; Wang C; Yu L
    Hematology; 2022 Dec; 27(1):609-619. PubMed ID: 35621728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.
    Diffner E; Beck D; Gudgin E; Thoms JA; Knezevic K; Pridans C; Foster S; Goode D; Lim WK; Boelen L; Metzeler KH; Micklem G; Bohlander SK; Buske C; Burnett A; Ottersbach K; Vassiliou GS; Olivier J; Wong JW; Göttgens B; Huntly BJ; Pimanda JE
    Blood; 2013 Mar; 121(12):2289-300. PubMed ID: 23327922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant NPM1 Maintains the Leukemic State through HOX Expression.
    Brunetti L; Gundry MC; Sorcini D; Guzman AG; Huang YH; Ramabadran R; Gionfriddo I; Mezzasoma F; Milano F; Nabet B; Buckley DL; Kornblau SM; Lin CY; Sportoletti P; Martelli MP; Falini B; Goodell MA
    Cancer Cell; 2018 Sep; 34(3):499-512.e9. PubMed ID: 30205049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML.
    Pianigiani G; Gagliardi A; Mezzasoma F; Rocchio F; Tini V; Bigerna B; Sportoletti P; Caruso S; Marra A; Peruzzi S; Petito E; Spinozzi G; Shacham S; Landesman Y; Quintarelli C; Gresele P; Locatelli F; Martelli MP; Falini B; Brunetti L
    Blood Adv; 2022 Nov; 6(22):5938-5949. PubMed ID: 36037515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A knock-in Npm1 mutation in mice results in myeloproliferation and implies a perturbation in hematopoietic microenvironment.
    Chou SH; Ko BS; Chiou JS; Hsu YC; Tsai MH; Chiu YC; Yu IS; Lin SW; Hou HA; Kuo YY; Lin HM; Wu MF; Chou WC; Tien HF
    PLoS One; 2012; 7(11):e49769. PubMed ID: 23226219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.
    Russ AC; Sander S; Lück SC; Lang KM; Bauer M; Rücker FG; Kestler HA; Schlenk RF; Döhner H; Holzmann K; Döhner K; Bullinger L
    Haematologica; 2011 Dec; 96(12):1783-91. PubMed ID: 21880628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleophosmin Mutants Promote Adhesion, Migration and Invasion of Human Leukemia THP-1 Cells through MMPs Up-regulation via Ras/ERK MAPK Signaling.
    Xian J; Shao H; Chen X; Zhang S; Quan J; Zou Q; Jin H; Zhang L
    Int J Biol Sci; 2016; 12(2):144-55. PubMed ID: 26884713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.
    Dawson MA; Gudgin EJ; Horton SJ; Giotopoulos G; Meduri E; Robson S; Cannizzaro E; Osaki H; Wiese M; Putwain S; Fong CY; Grove C; Craig J; Dittmann A; Lugo D; Jeffrey P; Drewes G; Lee K; Bullinger L; Prinjha RK; Kouzarides T; Vassiliou GS; Huntly BJ
    Leukemia; 2014 Feb; 28(2):311-20. PubMed ID: 24220271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological and clinical consequences of NPM1 mutations in AML.
    Heath EM; Chan SM; Minden MD; Murphy T; Shlush LI; Schimmer AD
    Leukemia; 2017 Apr; 31(4):798-807. PubMed ID: 28111462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NPM1c impedes CTCF functions through cytoplasmic mislocalization in acute myeloid leukemia.
    Wang AJ; Han Y; Jia N; Chen P; Minden MD
    Leukemia; 2020 May; 34(5):1278-1290. PubMed ID: 31831844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.
    Falini B
    Am J Hematol; 2023 Sep; 98(9):1452-1464. PubMed ID: 37317978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTCF boundary remodels chromatin domain and drives aberrant
    Luo H; Wang F; Zha J; Li H; Yan B; Du Q; Yang F; Sobh A; Vulpe C; Drusbosky L; Cogle C; Chepelev I; Xu B; Nimer SD; Licht J; Qiu Y; Chen B; Xu M; Huang S
    Blood; 2018 Aug; 132(8):837-848. PubMed ID: 29760161
    [No Abstract]   [Full Text] [Related]  

  • 20. Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor.
    Nemeckova S; Alexova-Zurkova K; Hainz P; Krystofova J; Mackova J; Roubalova K; Stastna-Markova M; Vrana M; Vydra J
    Curr Oncol; 2022 Apr; 29(5):2928-2934. PubMed ID: 35621629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.